Indication : 

Malignant Pleural Mesothelioma 

PEMECINE® in combination with Cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. 

Non-small cell lung cancer 

PEMECINE® in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. PEMECINE® is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

First line treatment should be platinum based with other cytotoxics chemotherapy. 

PEMECINE® is indicated as a single agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy (as second line). PEMECINE® is not indicated for treatment of patients with squamous non-small cell lung cancer.

Compositions :

Each vial contains Pemetrexed Disodium Hemipentahydrate 120.82 mg ~ Pemetrexed 100 mg

Each vial contains Pemetrexed Disodium Hemipentahydrate 604.10 mg ~ Pemetrexed 500 mg

Storage Condition : 

Store below 30°C. 

Shelf Life :

36 months